Mabwell (Shanghai) Bioscience Co., Ltd.
Equities
688062
CNE100005RD2
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.94 CNY | -1.53% |
|
-11.15% | -11.47% |
05-24 | Mabwell Announces 9MW2821 Clinical Data | CI |
05-13 | Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.47% | 1.59B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- 688062 Stock
- News Mabwell (Shanghai) Bioscience Co., Ltd.
- Mabwell Shanghai Bioscience's Unit Gets Nod to Hold Trial into Tumor Drug